source
- AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trialAbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is coden…Endpoints · 26d ago↗ source
- Endpoints Weekly highlights search for Alzheimer’s ‘statin’, Arrowhead’s tau-lowering injectable and AI Day recapEndpoints Weekly released its latest edition, previewing several biotech stories including a quest for a “statin of Alzheimer’s” and new data on Arrowhead’s injectable therapy that reduces tau prot…
- City Therapeutics raises $200 million in IPO, becoming 26th biotech listing of 2026